scholarly journals 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?

2018 ◽  
Author(s):  
Zeki Öngen
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Artery Disease

Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report

Platelets ◽  
2014 ◽  
Vol 26 (6) ◽  
pp. 593-597 ◽  
Author(s):  
Bernadeta Chyrchel ◽  
Justyna Totoń-Żurańska ◽  
Olga Kruszelnicka ◽  
Michał Chyrchel ◽  
Waldemar Mielecki ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Preliminary Report ◽  
Dual Antiplatelet Therapy ◽  
Platelet Reactivity ◽  
Artery Disease

scholarly journals 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease

2016 ◽  
Vol 152 (5) ◽  
pp. 1243-1275 ◽  
Author(s):  
Glenn N. Levine ◽  
Eric R. Bates ◽  
John A. Bittl ◽  
Ralph G. Brindis ◽  
Stephan D. Fihn ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Artery Disease

Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy

2008 ◽  
Vol 99 (11) ◽  
pp. 930-935 ◽  
Author(s):  
Rossella Marcucci ◽  
Roberto Caporale ◽  
Rita Paniccia ◽  
Eloisa Romano ◽  
Gian Franco Gensini ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Regression Analysis ◽  
Coronary Artery ◽  
High Risk ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Platelet Reactivity ◽  
Linear Regression Analysis ◽  
Immature Platelet Fraction ◽  
Artery Disease

SummaryA high platelet turnover rate produce a population of immature reticulated platelets (RP) that could confer, despite of antiplatelet drugs, a residual platelet reactivity (RPR) in coronary artery disease (CAD) patients. To assess the influence of RP on platelet reactivity in CAD patients on dual antiplatelet therapy we measured RP in 372 patients by using the Sysmex XE-2100 haematology analyzer and platelet function by optical platelet aggregometry (PA) on platelet-rich-plasma induced by 1 mmol arachidonic acid (AA-PA) and 10 μM ADP (ADP-PA). RPR was defined as either AA-PA >20% or ADP-PA >70%. RP were expressed as a percentage of RP of the total optical platelet count (immature platelet fraction; IPF) and as the percentage of RP highly fluorescent (higly fluorescent immature platelet fraction; H-IPF). Moderate but significant positive correlations between PA, IPF, H-IPF, and mean platelet volume (MPV) were found. According to tertiles of IPF, H-IPF and MPV, a significant trend for an increase of platelet aggregation by AA and ADP was evidenced. Furthermore, a significant difference for IPF, H-IPF and MPV between patients with and without RPR was observed. A linear regression analysis showed that IPF, H-IPF and MPV significantly affected PA measured by AA and ADP. At multivariate linear regression analysis these associations were confirmed. Moreover, a logistic regression analysis demonstrated that IPF, H-IPF and MPV significantly influenced the risk of RPR, and in the multivariate model these results remained significant. This study indicates that a high rate of platelet turnover is a new mechanism associated with platelet reactivity in high risk CAD patients on dual antiplatelet therapy.

Sign in / Sign up

Export Citation Format

Share Document